First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)
PHARMACEUTICAL PREPARATIONS
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is listed on Nasdaq, where it has traded since April 6, 2026.
- Listed On
- Nasdaq
- Listed Since
- April 6, 2026
- Market Cap
- $1.9B
About First Tracks Biotherapeutics, Inc. Ordinary Shares
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 141 institutions reported holding TRAX, with 32.5 million shares worth $654.1 million in aggregate. The largest reported holder was Ecor1 Capital, with 3.2 million shares worth $63.9 million. Of the 5 largest holders listed below, all 5 opened new positions in TRAX during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Ecor1 Capital | 3,174,519 | $64M | New position |
| Tcg Crossover Management | 2,895,304 | $58M | New position |
| Vanguard | 2,227,194 | $45M | New position |
| FMR | 2,054,127 | $41M | New position |
| Affinity Asset Advisors | 2,032,012 | $41M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TRAX?
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is listed on Nasdaq, where it has traded since April 6, 2026.
Who are the largest institutional holders of TRAX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TRAX were Ecor1 Capital, Tcg Crossover Management and Vanguard.
How many institutions own TRAX?
141 institutions reported a position in TRAX for the quarter ended June 30, 2026, worth $654.1 million in total.
Did institutions buy or sell TRAX last quarter?
Of the 5 largest reported holders, all 5 opened new positions in TRAX during the quarter. Every reported holder and its change is on the SentiSense ownership page for TRAX.
Every reported institutional holder, plus insider and congressional trades in TRAX, on SentiSense.